Resolvin E1 and E3 dampens asthmatic inflammation in a murine model

Abstract

Background: We previously reported that Resolvin E3(RvE3) dampens allergic airway inflammation in murine asthma model and suppresses the interleukin 23 pathway on bone marrow-derived dendritic cells(BMDCs). Though whether the efficacy of RvE3 is comparable to that of Resolvin E1(RvE1) is still unknown. Aims and Objects: We determined the effect of RvE1 and RvE3 on allergic airway inflammation using a murine model of asthma and BMDCs. Methods: In vivo, allergic airway inflammation was induced in BALB/c mice by House dust mite (HDM) sensitization and challenge (Day0-2,14-17) and RvE1 or RvE3 was administrated intraperitoneally after the last HDM challenge(Day17,18), and sacrificed on day 19. In vitro, BMDCs obtained from HDM-sensitized mice were stimulated with IL-33 and IL-4, then treated with RvE1 or RvE3 (10nM). Results: In vivo, both RvE1 and RvE3 treatment significantly decreased the number of total inflammatory cell and eosinophil in BAL fluid and the difference of efficacy between RvE1 and RvE3 were not significant. In vitro, both RvE1 and RvE3 treatment suppressed the IL-23 release from IL-33/IL-4 stimulated BMDCs. Conclusion: The efficacy of RvE3 on allergic airway inflammation is comparable to that of RvE1.